Literature DB >> 21921851

Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging in sudden sensorineural hearing loss: correlations with audiologic and vestibular testing.

In Sun Ryu1, Tae Hyun Yoon, Joong Ho Ahn, Woo Seok Kang, Byung Se Choi, Jeong Hyun Lee, Myung Joo Shim.   

Abstract

OBJECTIVE: Three-dimensional fluid-attenuated inversion recovery (3D-FLAIR) magnetic resonance imaging (MRI) has recently been applied to the inner ear, but the relationship between 3D-FLAIR findings and audiovestibular function has been unclear in patients with sudden sensorineural hearing loss (SSNHL). We therefore used 3D-FLAIR MRI to investigate vestibular lesions in patients with SSNHL and determined the correlation between these radiologic findings and results of audiovestibular function tests. STUDY
DESIGN: Prospective study.
METHODS: We enrolled 35 patients who presented with SSNHL from 2008 to 2009. Before treatment, all patients underwent audiovestibular evaluation including pure tone audiometry, electronystagmography, subjective visual vertical, subjective visual horizontal, vestibular evoked myogenic potential, and caloric tests. Pathologic conditions of the inner ears were evaluated by 3D-FLAIR at 3 Tesla, with and without gadolinium enhancement.
RESULTS: Of the 35 patients with SSNHL, 12 (34.3%) showed high signals in the affected inner ear on precontrast 3D-FLAIR MRI. Rates of abnormal results on all vestibular function tests were significantly higher for patients with vestibular lesions than those without vestibular lesions on FLAIR (p < 0.05). Vestibular lesions significantly correlated with the presence of vertigo (relative risk, 3.857; 95% confidence interval, 2.039-7.297) and occurrence of vestibular dysfunction (p < 0.05). There was a significant negative correlation between hearing recovery and positive findings on FLAIR (relative risk, -0.475; 95% confidence interval, -0.698 to -0.175; p = 0.004).
CONCLUSION: High signals in the affected inner ear on 3D-FLAIR MRI closely correlate with vestibular dysfunction and poor hearing recovery in patients with SSNHL, especially when the vestibular apparatus is involved.

Entities:  

Mesh:

Year:  2011        PMID: 21921851     DOI: 10.1097/MAO.0b013e31822e969f

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  MR Imaging in Sudden Sensorineural Hearing Loss. Time to Talk.

Authors:  G Conte; F Di Berardino; C Sina; D Zanetti; E Scola; C Gavagna; L Gaini; G Palumbo; P Capaccio; F Triulzi
Journal:  AJNR Am J Neuroradiol       Date:  2017-05-25       Impact factor: 3.825

2.  Injected 3T-3D-FLAIR-MRI labyrinthine patterns match with the severity and tonotopic alteration in sudden sensorineural hearing loss.

Authors:  L Compagnone; V Levigne; B Pereira; L Boyer; T Mom; S Mirafzal
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-03-14       Impact factor: 3.236

3.  A comparison of inner ear imaging features at different time points of sudden sensorineural hearing loss with three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging.

Authors:  Honglei Zhu; Yongkang Ou; Jia Fu; Ya Zhang; Hao Xiong; Yaodong Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-06       Impact factor: 2.503

4.  Heavily T₂-Weighted 3D-FLAIR Improves the Detection of Cochlear Lymph Fluid Signal Abnormalities in Patients with Sudden Sensorineural Hearing Loss.

Authors:  Shinji Naganawa; Hisashi Kawai; Toshiaki Taoka; Kojiro Suzuki; Shingo Iwano; Hiroko Satake; Michihiko Sone; Mitsuru Ikeda
Journal:  Magn Reson Med Sci       Date:  2015-11-20       Impact factor: 2.471

5.  Vestibular Dysfunctions in Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis.

Authors:  Huiqian Yu; Huawei Li
Journal:  Front Neurol       Date:  2018-02-05       Impact factor: 4.003

6.  Clinical value of vestibular-evoked myogenic potential tests in patients with sudden sensorineural hearing loss.

Authors:  Yuan Wang; Shun-Tong Gu; Xiao-Lin Bao; Jia-Liang Guo
Journal:  BMC Neurol       Date:  2019-12-21       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.